Skip to main content
. 2021 Jun 30;35:100831. doi: 10.1016/j.ijcha.2021.100831

Table 1.

Clinical characteristics of the total study population and in patients with and without myocardial ischemia.

Total population (n = 125) Ischemia (n = 66) No ischemia (n = 59) p
Clinical characteristics
Age (years) 62 ± 9 63 ± 9 62 ± 9 0.355
Female sex 72 (58%) 36 (55%) 36 (61%) 0.465
BMI (kg/m2) 27.6 ± 4.5 27.1 ± 4.1 28.1 ± 4.9 0.247
Obesity 28 (22%) 10 (15%) 18 (31%) 0.040
Hypertension 92 (74%) 53 (80%) 39 (67%) 0.097
Diabetes 17 (14%) 8 (13%) 9 (16%) 0.862
Current smoker 18 (14%) 8 (12%) 10 (17%) 0.445
Family history of premature CAD 71 (57%) 34 (52%) 37 (63%) 0.139
Chest pain ≥ 6 months 94 (75%) 50 (76%) 44 (75%) 0.879
Dyspnea ≥ 6 months 83 (66%) 44 (67%) 39 (66%) 0.947
Systolic blood pressure (mmHg) 134 ± 16 134 ± 16 135 ± 16 0.774
Diastolic blood pressure (mmHg) 78 ± 13 78 ± 12 78 ± 13 0.927
Heart rate (bpm) 65 ± 12 66 ± 11 63 ± 12 0.167
HbA1c (mmol/mol) 39 ± 9 39 ± 7 39 ± 10 0.986
Estimated GFR (mL/min/1.73 m2) 86 ± 14 87 ± 15 84 ± 13 0.292
Total serum cholesterol (mmol/L) 5.1 ± 1.3 5.1 ± 1.4 5.0 ± 1.1 0.780
Serum HDL cholesterol (mmol/L) 1.5 ± 0.4 1.5 ± 0.5 1.5 ± 0.4 0.850
Serum LDL cholesterol (mmol/L) 3.3 ± 1.2 3.3 ± 1.3 3.2 ± 1.0 0.791
Serum triglycerides (mmol/L) 1.48 ± 0.98 1.56 ± 0.85 1.40 ± 1.11 0.327



Medical therapy
Acetylsalicylic acid 51 (41%) 32 (49%) 19 (32%) 0.027
Statin 46 (37%) 25 (38%) 21 (36%) 0.543
Antihypertensive treatment 64 (51%) 34 (52%) 30 (51%) 0.663
Beta blocker 34 (27%) 14 (21%) 20 (34%) 0.154
Calcium channel blocker 21 (17%) 15 (23%) 6 (10%) 0.056
Angiotensin converting enzyme inhibitor 8 (6%) 4 (6%) 4 (7%) 0.936
Angiotensin 2 receptor inhibitor 38 (30%) 25 (38%) 13 (22%) 0.039

BMI, body mass index; CAD, coronary artery disease; bpm, beats per minute; HbA1c, hemoglobin A1c, GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.